BCP402 / Biocure Technology - LARVOL DELTA

Biocure Technology Inc. Announces Focus on its own CAR T-cell Therapy Targeting Chronic Lymphocytic Leukemia (“CLL“) and Solid Tumor Cancers and Intent to Apply for Patents (Biocure Press Release) - “BiocurePharm Corp….announce its focus on the development of its own CAR T-cell therapy targeting Chronic lymphocytic leukemia and solid tumor cancers. BPK is using an innovative concept of ROR1 CAR T-cell therapy combined with a double specific antibody model. In conjunction with the development of its own CAR T, the Company plans to apply for patents covering this CAR T-cell cancer therapy technology. The Company will also be able to apply the same platform technology to develop it’s CAR T-cell therapy for Solid tumors such as Ovarian and Lung cancers, which provide further enormous opportunities for the Company...The Company, has recently strengthened its board to focus on it’s own developed technology and is looking forward to obtaining its own patents where there are currently no restrictions, which is in contrast to CD-19 Car T therapy."

Clinical • Chronic Lymphocytic Leukemia • Gynecologic Cancers • Hematological Malignancies • Leukemia • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor